Information Provided By: 
Fly News Breaks for September 29, 2019
LIVN
Sep 29, 2019 | 17:16 EDT
Piper Jaffray analyst Matt O'Brien notes that LivaNova announced it had enrolled the first patient in its CMS approved RECOVER clinical study. Although the timing is in-line with management's expectations, there had been some concern that it would slip, he notes, adding that the announcement is "certainly positive" and "an important step" for the company's topline outlook. On the whole, the analyst believes the announcement serves as a starting point for eventual coverage. O'Brien reiterates an Overweight rating and $90 price target on the shares.
News For LIVN From the Last 2 Days
There are no results for your query LIVN
